Rituximab: A Hope for Lymphoma Patients

Ahmed M. Kabel^{1, 2,} , Ashwaq M. Al-Asmari³, Maha J. Al-Gamdi³, Rahaf S. Al-Qurashi³, Abeer A. Al-Shehri³ and Arwa M. Al-Sudani³

¹Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, KSA

²Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

³Fifth year student, College of Pharmacy, Taif University, Taif, KSA

Cite this paper:
Ahmed M. Kabel, Ashwaq M. Al-Asmari, Maha J. Al-Gamdi, Rahaf S. Al-Qurashi, Abeer A. Al-Shehri and Arwa M. Al-Sudani. Rituximab: A Hope for Lymphoma Patients. Journal of Cancer Research and Treatment. 2016; 4(1):17-20. doi: 10.12691/jcrt-4-1-3

Abstract

Rituximab is an antibody targeting the CD20 receptor protein of B-cells, the immune cell responsible for specific adaptive immune system properties. In B-cell lymphomas, where the B-cell lymphatic cells underlie the lymphoma phenotype, the use of rituximab to specifically target and destroy B-cells is a relatively recent strategy for treating lymphomas. Indeed, even recently it has been determined that classic Hodgkin’s lymphoma can be treated by a special regimen of rituximab. Rituximab had such a pronounced effect on the survival rates of certain lymphomas that the survival outcomes have fundamentally changed. These outcomes have changed to the degree that prognostic tools used to infer survival rates have had to be overhauled. The exact molecular mechanisms of rituximab activity had recently been elucidated, and although heterogeneity in lymphoma response to rituximab exists, detailed molecular studies investigating this have as a result uncovered new molecular targets, such as CD55 and CD59. The above mentioned topics, as well as the toxicity of rituximab, the use of rituximab with supplemental treatments in parallel such as histone deacetylase inhibitors, radiation therapy, and the effects of rituximab on different types of lymphomas, are all reviewed here.

Keywords:
rituximab lymphoma patients

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Abdel-Rahman MN, Kabel AM. Comparative study between the effect of methotrexate and valproic acid on solid Ehrlich tumour. J Egypt Natl Canc Inst 2012; 24(4):161-7.
[2]	Jerónimo M, Silva S, Benedito M, Brito MJ. Hodgkin'´s Lymphoma and Autoimmunity: Is There a Relationship?. Acta Med Port 2015; 28(6):749-53.
[3]	Okamoto A, Yanada M, Inaguma Y, Tokuda M, Morishima S, Kanie T, et al. Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab: A single-center experience. Hematology 2013; 18(2):74-80.
[4]	Chen Q, Ayer T, Nastoupil LJ, Rose AC, Flowers CR. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health 2015; 18(2):189-97.
[5]	Lunning MA, Armitage JO. Rituximab Maintenance Therapy In Diffuse Large B-Cell Lymphoma: Is XY The Most Important Variable?. Haematologica 2015; 100: 853-5.
[6]	Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993;121(5):1121-32.
[7]	Weiner GJ. Rituximab: mechanism of action. Seminars in hematology 2010; 47(2):115-23.
[8]	Vitolo U, Chiappella A, Angelucci E, Rossi G, liberati AM, Cabras MG, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 2009; 94(9):1250-8.
[9]	Dabaja BS , Vanderplas AM , Crosby-Thompson AL , Abel GA , Czuczman MS , Friedberg JW, et al. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer 2015; 121(7):1032-9.
[10]	Thompson RC, Vardinogiannis I, Gilmore TD. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS One 2013; 8(5):e62822.
[11]	Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, et al. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica 2015; 100(3):357-62.
[12]	Roullet MR, Martinez D, Ma L, Fowler MH, McPhail ED, Judkins A, et al. Coexisting follicular and mantle cell lymphoma with each having an in situ component: A novel, curious, and complex consultation case of coincidental, composite, colonizing lymphoma. Am J Clin Pathol 2010;133(4):584-91.
[13]	Arcaini L, Merli M. Rituximab maintenance in follicular lymphoma patients .World Journal of Clinical Oncology 2011; 2(7):281-8.
[14]	Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2013; 110(4):1398-403.
[15]	Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012; 119(18):4129-32.
[16]	Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123(6):837-42.
[17]	Dotan E, Aggarwal C, Smith MR. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin’s Lymphoma. Pharmacy and Therapeutics 2010; 35(3):148-157.
[18]	Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008;59:237-50.
[19]	Miranda-Hernández MP, López-Morales CA, Ramírez-Ibáñez ND, Piña-Lara N, Pérez NO, Molina-Pérez A, et al. Assessment of Physicochemical Properties of Rituximab Related to Its Immunomodulatory Activity. Journal of Immunology Research 2015; 2015: Article ID 910763.
[20]	Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95:3900-8.
[21]	Du J, Wang H, Zhong C, Peng B, Zhang M, Li B, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem 2007; 282(20):15073-80.
[22]	Lee L, Crump M, Khor S, Hoch JS, Luo J, Bremner K, et al. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Br J Haematol 2012; 158(4):481-8.
[23]	Thieblemont C, Brière J. MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?. Blood 2013 121 (12): 2165-6.
[24]	Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, Tan KL, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol 2014;165(3):382-91.
[25]	Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013; 121(20): 4021-31.
[26]	Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 2013; 98(2):255-63.